Pfizer's latest plot twist includes an expanded European nod for its RSV vaccine, ABRYSVO, and a new autoimmune collab with ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Analysts at BMO Capital Markets expressed that this departure might undermine the FDA's mission, stressing that the agency's independence is vital for delivering safe and effective treatments. As the ...

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...

Vaxcyte’s stock has dropped around 45% despite a Phase II trial of its invasive pneumococcal disease (IPD) vaccine meeting ...

Pfizer has won European Commission expanded approval of its Abrysvo vaccine for respiratory syncytial virus, or RSV, for use in all adults. The New York drugmaker on Tuesday said the extended ...

The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...

Pfizer delayed the announcement of its COVID-19 vaccine until after the 2020 election when it thought Donald Trump was ...

Shares in Moderna, Vaxcyte, Novavax and BioNTech all fell Monday after Peter Marks, head of the FDA office that reviews ...

Dr. Peter Marks, a veteran of the agency, wrote that undermining confidence in vaccines is irresponsible and a danger to ...

Pfizer (PFE) and other COVID shot makers such as Moderna (MRNA) will face investor scrutiny as FDA's top vaccine regulator Dr ...

Just two days after Democrat Joe Biden was declared the winner of the 2020 presidential election, drugmaker Pfizer announced ...